Group items matching

in title, tags, annotations or url

When I was asked by fellow independent contractors to join the Review Steering Group (RSG) back in late 2020, I said yes, because I wanted, fundamentally, to look for some ways to improve both LPCs and PSNC. Through my experiences with Greater Manchester LPC I had seen the sorts of changes that LPCs could make and the positive impact that those had on local engagement and in allowing us to do more to support contractors: I wanted to help share what we had learned with the rest of the country. I was pretty sure that the national negotiator could make some positive changes as well. It took longer than I had hoped. And it was a lot harder than I had imagined - not least because of the extent of some of the divisions within our sector - but after 15 months of hard work, I'm pleased with where we have got to, and I believe the 37 changes being proposed will help all contractors. Consensus is not a sexy word. It is not something that fires up our imaginations or that we put on our list of key work objectives for the year. It is also not something that might come naturally to us as independent contractors. But consensus is something that matters. It is the thing that allows us, as a vibrant and diverse group of businesses, to see beyond our differences and to fight together for outcomes that benefit every single one of us. Consensus is also the thing that the RSG has been relentlessly focused on throughout its work, and it's at the heart of what will give our LPCs and PSNC a stronger voice for community pharmacy in the future.

The National Institute for Health and Care Excellence (NICE) has recommended faricimab as treatment option for adults with wet age-related macular degeneration or diabetic macular oedema. Thousands of people in England could benefit from the recommendation of a new drug that helps to treat two leading causes of sight loss and visual impairment. Faricimab is administered as an eye injection and is being recommended as an option for treating some adults with wet age-related macular degeneration (AMD) or with diabetic macular oedema (DMO). In the key clinical trials, aflibercept, another eye injection drug used to treat AMD and DMO, was administered every 8 weeks, while faricimab dosing, based on assessments of the disease activity, allowed for an interval of up to 16 weeks between doses, and was found to be equally effective. Up to 300,000 people in England with wet age-related macular degeneration (AMD) could be eligible to receive faricimab as part of their treatment alongside just over 28,000 people with diabetic macular oedema.

The National Institute for Health and Care Excellence (NICE) has recommended pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel) which is said to benefit people with triple negative breast cancer. Clinical trial evidence shows that, compared with paclitaxel, pembrolizumab combination increases how long people have before their cancer gets worse and how long they live. NICE already recommends atezolizumab in combination with chemotherapy for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer. Atezolizumab combination is recommended by NICE for people with IC equal to or greater than 1%. "This means that some people who can't have atezolizumab combination could be eligible for pembrolizumab combination," said NICE. NICE's independent appraisal committee also agreed that the pembrolizumab combination meets the higher cost-effectiveness threshold for life-extending treatments for people with a short life expectancy. Given by injection every 3 weeks, pembrolizumab (also called Keytruda and made by Merck Sharp and Dohme) is a type of immunotherapy that specifically targets triple negative breast cancer. It works by blocking the activity of a protein known as PD-L1 which is produced in larger amounts on cancerous cells than normal cells. By blocking PD-L1 it helps the person's own immune cells to attack the cancer.

Two weeks prior to the closing of the hub and spoke consultation, issues around patient safety, costs and competition as well as practicalities such as what to do with uncollected medicines were discussed in a webinar on hub and spoke dispensing on Wednesday (May 26). The webinar was organised by Sigma Pharmaceuticals in association with the National Pharmacy Association (NPA). NPA director of corporate affairs Gareth Jones chaired the event and was joined by Sigma's Hatul Shah and Raj Haria as well as NPA vice chair Nick Kaye and NPA head of advice and support services Jasmine Shah. Kaye said: "There are still many 'unknown unknowns' with hub and spoke and the jury's still out on any potential benefits. I have lots of reservations about cost and it worries me how efficient this is for the business and the long term sustainability for the sector as a whole. Above all we need to think about the patient at the centre of all this and the potential confusion for them." Jasmine Shah felt patient safety was going to be the key in regards to whether the spoke and the hub would hold the ultimate responsibility and "who is going to take the accountability as far as patient care goes". She added: "It is most important that GPhC standards and NHS requirement are both met in identifying all the risks associated with the arrangement with hub and spoke and ensuring that (patient safety) measures are in place. Everything that needs to be looked at is by putting the patient at heart of the arrangement and seeing what is the safest way for them to receive care from both spoke and hub."

As part of its centenary celebrations, the National Pharmacy Association (NPA) has raised more than eleven thousand pounds for mental health charity Mind. A total of £11,583 was raised for Mind and the Association continues to encourage members to support the charity. The NPA marked its 100th birthday in 2021 and partnered with Mind in England and Wales, and equivalent charities in Scotland and Northern Ireland - SAMH (Scottish Association for Mental Health) and Inspire Wellbeing - to raise awareness of pharmacy services for people with mental health problems and to generate funds for the work of these charities. The NPA held set-piece events, such as sponsored walks, and pharmacists, colleagues and their families and friends were encouraged to organise their own activities. Chief executive of the NPA, Mark Lyonette, said: "I was delighted to be at our sponsored walk in St Albans, home of our head office, last year. This and other fundraising events all underlined the message that community pharmacies are concerned with the wellbeing of the whole person - mind as well as body."

To ease pressure on community pharmacies, the deadline to meet the requirements of the Pharmacy Quality Scheme will be extended, Pharmaceutical Services Negotiating Committee (PSNC) announced today (December 15). This follows an agreement reached between the negotiator and the NHS England and NHS Improvement (NHSE&I) and the Department of Health and Social Care (DHSC). Recognising the challenges faced by pharmacies and their contribution towards the Covid-19 vaccination programme, following additional changes have been agreed upon: Contractors will not be required to complete the Community Pharmacy Patient Questionnaire for 2021/2022; The requirement for pharmacy teams to complete a national audit (intended to be on valproate) in 2021/22 will be waived; and The requirement for pharmacy teams to complete a contractor-chosen clinical audit in 2021/22 will be waived.

Acknowledging publication of the Royal Pharmaceutical Society (RPS) Scotland's new professional vision for the future of pharmacy in Scotland - Pharmacy 2030, a Parliamentary Motion has been lodged in the Scottish Parliament. The vision, produced in collaboration with the National Pharmacy Technician Group Scotland, expects all pharmacists in a patient-facing role to become independent prescribers by 2030. The motion recognised the aim of the publication that by 2030 pharmacy teams will work together, using their expertise to make the best use of medicines and, will take a person-centred approach, providing care holistically rather than by clinical condition. It highlighted the important role that RPS would play by working with partners across health and social care to turn this vision into a reality.

Health secretary Sajid Javid visited Medicine Chest Pharmacy in London on Friday (January 28) and thanked pharmacy teams across England for delivering well over 20 million Covid-19 jabs. According to the latest research conducted by the National Pharmacy Association (NPA) and PharmData, independent community pharmacies were the biggest deliverers of Covid-19 vaccines during January 2021 to September 2021 as compared to corporate-run pharmacy sites. As of January 2022, pharmacies across the whole sector had delivered 22 million Covid jabs, with the majority of them being independents of whom most are NPA members. In a video message released after the visit, Javid said: "Today I am here at Medicine Chest pharmacy in London to thank them, all pharmacies, the NHS, for the fantastic job they have done particularly over the last few months to get our country boosted. It's because of this phenomenal success that today we are able to return to Plan A as we see Omicron in retreat and we learn to live with Covid."

More than half of pharmacists working in England are considering changing their roles over the next 12-18 months because of work-related issues, a recent survey by The Pharmacists' Defence Association revealed. The survey which concluded on February 18, 2022 had more than 2,500 participants including employed and locum pharmacists from all four UK nations. In the survey, PDA asked respondents about their current roles and future career plans. The initial feedback showed that unsatisfactory pay and working environments, lack of professional fulfilment, and poor management were the key factors for pharmacy professionals to reconsider their current positions.

Thirty-five generic drug manufacturers will make a more affordable version of Pfizer's anti-Covid pill for the world's poorer nations, in licensing deals announced Thursday (17) by a UN-backed organisation. The global Medicines Patent Pool (MPP) signed agreements with three dozen manufacturers to produce the oral Covid-19 treatment nirmatrelvir for supply in 95 low- and middle-income countries. US pharmaceutical giant Pfizer signed a licence agreement with the MPP in November. The MPP, in turn, issued sub-licences to the generic drugs makers. The deals announced Thursday will "help ensure access to our oral Covid-19 treatment for patients in need around the world", said Pfizer chairman Albert Bourla.

The National Institute for Health and Care Excellence (NICE) has recommended icosapent ethyl also called Vazkepa manufactured by Amarin for adults who have cardiovascular disease with controlled LDL-C levels taking a statin. It's final draft guidance is expected to be available on the July 20. Nearly half a million people are expected to benefit from the first licensed treatment shown to reduce the risk of heart attacks and strokes in people with controlled low-density lipoprotein cholesterol (LDL-C - sometimes called "bad" cholesterol) who are taking a statin and who have raised levels of triglycerides. NICE said: "Clinical trial evidence suggests that for people with raised triglycerides who have LDL-C levels controlled by statins, and who have cardiovascular disease, icosapent ethyl reduces their risk of cardiovascular events by over a quarter compared with placebo. Helen Knight, interim director of medicines evaluation at NICE, said: "Icosapent ethyl is the first licensed treatment of its kind for people who are at risk of heart attacks and strokes despite well controlled LDL cholesterol because they have raised blood fats. And although lifestyle changes, including diet and exercise, can help to reduce their risk, these may not work for everyone.

Health and Social Care Secretary Sajid Javid and Madelaine McTernan, head of the HRT supply taskforce, continue to take urgent action to resolve the shortage of HRT medicines by meeting the drug manufacturers and representatives from community pharmacies on Thursday (May 5). In the meeting, manufacturers outlined the steps they're taking to boost supply, and pharmacists shared their experiences on the frontline, as well as sharing their thoughts on wider solutions including improved communications. Aspen Pharmacare, Besins-Healthcare, Gedeon Richter, Novartis, Novo Nordisk, Orion, Pfizer, Theramex, Viatris, and representatives from community pharmacies were part of the meeting. As the government confirmed its intention to work with industry to do what is necessary to fix the HRT supply issue, Javis said he wanted to understand the issues facing suppliers and what can be done to address them. "We will leave no stone unturned in our national mission to boost supply of HRT. Along with appointing Madelaine McTernan as head of the HRT supply taskforce to implement lessons learned from the pandemic, and ensuring prescriptions are issued in shorter cycles for now, we are working collectively with the sector to urgently resolve this issue," he commented. The Association of Independent Multiple Pharmacies (AIMp) said the meeting discussed 'why we got into this position' and the way forward.

Numark is set to launch a large-scale broadcast campaign to promote its Hey Pharmacist repeat prescription service on May 22. The new campaign introduces, 'Repeat prescriptions. Made simple,' with a set of three TV adverts that feature three different heightened-reality scenarios. In each advert, the hero discovers they have forgotten to order their repeat prescription at a less than ideal time but thanks to Hey Pharmacist, a few taps later their problems are solved. The adverts highlight how managing your repeat prescriptions has never been quicker or simpler in a tongue-in-cheek, comedic tone. The campaign - which incorporates national broadcast and SkyAdSmart TV alongside digital, social, and in-store campaigns across England - promotes the Hey Pharmacist app which provides Numark members in England with an end-to-end online repeat prescription proposition, helping them deliver a best-in-class digital capability which highlights the benefits for patients who choose to collect their medication from their local Numark pharmacy. Jeremy Meader, managing director of Numark, commented: "It is very exciting to see our first TV campaign go live. The creative does a brilliant job in bringing to life the benefits of Hey Pharmacist, highlighting how easy and effortless managing prescriptions can be. We look forward to assisting more everyday heroes and supporting our members in showcasing this exciting digital proposition to a larger audience."

Community pharmacy should be involved in key decisions in neighbourhoods and systems to help reduce workload and increase patient access, a roundtable organised by the National Pharmacy Association to discuss a recent review on primary care integration has concluded. The NPA said it would be sending the recently published report on the roundtable to local pharmaceutical committees (LPCs) and other local pharmacy leaders as a tool to help them engage with Integrated Care Systems (ICSs) which will become statutory bodies from July 1. The 'Fuller Stocktake: Community Pharmacy Roundtable' report, published on June 13 by the NPA, is based on a meeting hosted by the association on behalf of the NHS team running a key review of primary care integration, the so-called 'Fuller Stocktake'. NPA integration lead, Michael Lennox, said: "The NPA recognises the critical importance of our LPC network colleagues being there for contractors at the 42 local systems level and influencing to fulfil the laudable ambitions of the Fuller Report. "We ensured that community pharmacy voices were heard in the stocktake process and now that conversation needs to be amplified locally."

The Royal Pharmaceutical Society (RPS) has published a new professional guidance for prescribing practice on Monday (June 6) which it says will be "for the benefit of all independent prescribers across the UK". Based on collaboration with multi-professional stakeholders, the document is a guidance tool for prescribers wanting to expand their prescribing scope of practice. Commissioned by the Welsh government, the document was developed through an expert group with representatives from many healthcare professions, including from Higher Education institutions, professional bodies, regulatory bodies, the National Institute for Health and Care Excellence, NHS Education for Scotland, Health Education and Improvement Wales, and representatives from hospital, community and GP practice. RPS president Claire Anderson said: "It's fantastic to see the growth in prescribing, both across the profession and more widely, to improve patient care.

The age at which people can buy tobacco in England should rise by one each year until it becomes a "smoke-free" society, a government-commissioned review recommended on Thursday (June 9). The minimum age today is 18. But the review by Javed Khan, former head of children's charity Barnardo's, advised raising it annually until eventually no one can buy tobacco products. His review recommends 15 interventions to help the government meet its national target to be smoke-free by 2030, including the promotion of vaping to help smokers quit. "Without immediate and sustained action, England will miss the smoke-free target by many years and most likely decades," said Khan. "A smoke-free society should be a social norm -- but to achieve this, we must do more to stop people taking up smoking, help those who already smoke and support those who are disproportionately impacted by smoking."

Prince Charles has praised the "dedication and professionalism of pharmacy staff" at an event held in London to celebrate the work of community pharmacists during the Covid-19 pandemic. Two hundred pharmacists, pharmacy staff and other health service representatives were invited to attend a special reception hosted by His Royal Highness at St James's Palace on Wednesday night (May 4). According to the National Pharmacy Association, the event was held, in part, to mark the NPA's recent centenary. In his closing speech, The Prince of Wales paid tribute to the work of pharmacies on the NHS frontline. He praised "the dedication and professionalism of pharmacy staff" during the Covid-19 pandemic and said: "I very much hope that this evening's event will help, a little bit, to highlight the marvellous work you do in your communities day in and day out."

Following concerns raised about cracked cartridges and insulin leaks, the Medicines and Healthcare products Regulatory Agency (MHRA) has issued a national patient safety alert for the NovoRapid PumpCart prefilled insulin cartridge and the Roche Accu-Chek Insight Insulin pump system. The regulator have asked patients to check the pre-filled glass insulin cartridge for cracks before use. It advised against using the cartridge if it has been dropped even if no cracks are visible and urged to closely follow the updated handling instructions in the pump user manual when changing pre-filled glass insulin cartridges. In some of the reported leakage incidents, the cartridges were found to be cracked and provided an inadequate supply of insulin to patients. Leakages also occurred in cases where no cracks in the cartridge were visible, the regulator said. In some patients there were consequences of not receiving enough insulin from their pump system, including reports of severely high blood sugar and diabetic ketoacidosis, a serious complication of diabetes when the body produces high levels of blood acids called ketones. Healthcare professionals are being advised to contact patients over the next six months using said device to discuss their individual needs and source an alternative pump where appropriate. "Because of the rare risk of insulin leakage from the Roche Accu-Chek Insight Insulin Pump, patients should check the pre-filled glass insulin cartridge for any cracks prior to usage," Dr June Raine, MHRA chief executive, said.

The National Pharmacy Association (NPA) is asking independents to vote 'yes' to reform of pharmacy representation in England as a three-week voting period opens on Friday, May 27. The NPA is also calling on PSNC to complete unfinished business and present 'the compelling case for change' that the Review Steering Group was unable to deliver. The Associations says it is "on balance" and with some degree of reluctance supporting an affirmative vote, because the benefits marginally outweigh the several valid arguments for a "no" vote. NPA chief executive, Mark Lyonette, said on Thursday (May 19): "After much deliberation and engagement with members, we are recommending our members vote yes, because the alternatives are either the flawed status quo or a further period of uncertainty for the sector, with months or even years of introspection to come. There is no guarantee that going back to the drawing board, particularly with the same actors, would bring about a better outcome.

Community pharmacists are readily accessible healthcare providers and medicine experts in the community setting and their counsel is often sought by patients and consumers on a number of subjects including the use of dietary supplements. Their role in the sale of and advice regarding natural health and drug alternatives has never been more relevant. The recent National Health Service (NHS) Interim People Plan calls for the NHS to put all staff front and centre of the way it operates and identifies pharmacists as a critical part of multidisciplinary teams, providing care across a wide range of increasingly complex patient needs. Despite existing demand to counsel patients on a vast range of medicines, more and more consumers are looking to their pharmacist to support and enhance their knowledge regarding the relevance of a growing range of supplementary nutrients now available. Nutritional supplementation is increasingly becoming the consumer's first choice for 'drug free' treatment or natural prevention that provides a true sense of taking control, which the prescription process often denies them. The vast and growing depository of information on the internet is certainly fuelling this, but as much of this is brand derived content, information, it can often be generic with a 'one size fits all' marketing message.